Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting

Detalhes bibliográficos
Autor(a) principal: Sabbatani,Sergio
Data de Publicação: 2006
Outros Autores: Giuliani,Ruggero, Manfredi,Roberto
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Infectious Diseases
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000400012
Resumo: The elevated frequency of chronic hepatitis C virus (HCV) infection found among prison inmates, and the availability of improved pharmacological cure for this potentially life-threatening disorder, make investigations conducted in this somewhat neglected area very relevant, since only a few, open-label experiences have been reported till now. In the metropolitan prison of Bologna (Italy), HCV seroprevalence was found to be over 31% in 2003, so that a pilot feasibility study based on treatment with pegylated interferon plus ribavirin was initiated, after careful counseling carried out by a joint commission of health care personnel of the correctional facility and infectious diseases consultants. Thirty-nine patients were enrolled, and despite expected dropouts due to difficulty in maintaining the same level of counseling pressure over time, and the particularly unfavorable climatic conditions during Summer 2003, a sustained virological response was obtained for 8 out of the 21 patients who remained evaluable after the first three month follow-up, although we need to take into account that a high percentage of subjects (67%) were selected for therapy due to their favorable HCV genotypes (types 2 and 3). Our preliminary experience shows that an intrinsically complicated therapy, such as the administration of pegylated interferon plus ribavirin, can attain a relatively high success rate, even in a very unfavorable and uncomfortable context, such as a prison, where only enforced counseling, active participation of institutional health care operators, and patient's willingness to maintain an elevated level of co-operation and adherence, can overcome most structural and relational difficulties.
id BSID-1_abdb7df70d5dc3a84a97f4a95b0e4cb8
oai_identifier_str oai:scielo:S1413-86702006000400012
network_acronym_str BSID-1
network_name_str Brazilian Journal of Infectious Diseases
repository_id_str
spelling Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison settingChronic hepatitis Cpegylated interferonribavirinmanagementinmatesprisonThe elevated frequency of chronic hepatitis C virus (HCV) infection found among prison inmates, and the availability of improved pharmacological cure for this potentially life-threatening disorder, make investigations conducted in this somewhat neglected area very relevant, since only a few, open-label experiences have been reported till now. In the metropolitan prison of Bologna (Italy), HCV seroprevalence was found to be over 31% in 2003, so that a pilot feasibility study based on treatment with pegylated interferon plus ribavirin was initiated, after careful counseling carried out by a joint commission of health care personnel of the correctional facility and infectious diseases consultants. Thirty-nine patients were enrolled, and despite expected dropouts due to difficulty in maintaining the same level of counseling pressure over time, and the particularly unfavorable climatic conditions during Summer 2003, a sustained virological response was obtained for 8 out of the 21 patients who remained evaluable after the first three month follow-up, although we need to take into account that a high percentage of subjects (67%) were selected for therapy due to their favorable HCV genotypes (types 2 and 3). Our preliminary experience shows that an intrinsically complicated therapy, such as the administration of pegylated interferon plus ribavirin, can attain a relatively high success rate, even in a very unfavorable and uncomfortable context, such as a prison, where only enforced counseling, active participation of institutional health care operators, and patient's willingness to maintain an elevated level of co-operation and adherence, can overcome most structural and relational difficulties.Brazilian Society of Infectious Diseases2006-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000400012Brazilian Journal of Infectious Diseases v.10 n.4 2006reponame:Brazilian Journal of Infectious Diseasesinstname:Brazilian Society of Infectious Diseases (BSID)instacron:BSID10.1590/S1413-86702006000400012info:eu-repo/semantics/openAccessSabbatani,SergioGiuliani,RuggeroManfredi,Robertoeng2007-02-02T00:00:00Zoai:scielo:S1413-86702006000400012Revistahttps://www.bjid.org.br/https://old.scielo.br/oai/scielo-oai.phpbjid@bjid.org.br||lgoldani@ufrgs.br1678-43911413-8670opendoar:2007-02-02T00:00Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)false
dc.title.none.fl_str_mv Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
title Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
spellingShingle Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
Sabbatani,Sergio
Chronic hepatitis C
pegylated interferon
ribavirin
management
inmates
prison
title_short Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
title_full Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
title_fullStr Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
title_full_unstemmed Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
title_sort Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
author Sabbatani,Sergio
author_facet Sabbatani,Sergio
Giuliani,Ruggero
Manfredi,Roberto
author_role author
author2 Giuliani,Ruggero
Manfredi,Roberto
author2_role author
author
dc.contributor.author.fl_str_mv Sabbatani,Sergio
Giuliani,Ruggero
Manfredi,Roberto
dc.subject.por.fl_str_mv Chronic hepatitis C
pegylated interferon
ribavirin
management
inmates
prison
topic Chronic hepatitis C
pegylated interferon
ribavirin
management
inmates
prison
description The elevated frequency of chronic hepatitis C virus (HCV) infection found among prison inmates, and the availability of improved pharmacological cure for this potentially life-threatening disorder, make investigations conducted in this somewhat neglected area very relevant, since only a few, open-label experiences have been reported till now. In the metropolitan prison of Bologna (Italy), HCV seroprevalence was found to be over 31% in 2003, so that a pilot feasibility study based on treatment with pegylated interferon plus ribavirin was initiated, after careful counseling carried out by a joint commission of health care personnel of the correctional facility and infectious diseases consultants. Thirty-nine patients were enrolled, and despite expected dropouts due to difficulty in maintaining the same level of counseling pressure over time, and the particularly unfavorable climatic conditions during Summer 2003, a sustained virological response was obtained for 8 out of the 21 patients who remained evaluable after the first three month follow-up, although we need to take into account that a high percentage of subjects (67%) were selected for therapy due to their favorable HCV genotypes (types 2 and 3). Our preliminary experience shows that an intrinsically complicated therapy, such as the administration of pegylated interferon plus ribavirin, can attain a relatively high success rate, even in a very unfavorable and uncomfortable context, such as a prison, where only enforced counseling, active participation of institutional health care operators, and patient's willingness to maintain an elevated level of co-operation and adherence, can overcome most structural and relational difficulties.
publishDate 2006
dc.date.none.fl_str_mv 2006-08-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000400012
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000400012
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1413-86702006000400012
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
dc.source.none.fl_str_mv Brazilian Journal of Infectious Diseases v.10 n.4 2006
reponame:Brazilian Journal of Infectious Diseases
instname:Brazilian Society of Infectious Diseases (BSID)
instacron:BSID
instname_str Brazilian Society of Infectious Diseases (BSID)
instacron_str BSID
institution BSID
reponame_str Brazilian Journal of Infectious Diseases
collection Brazilian Journal of Infectious Diseases
repository.name.fl_str_mv Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)
repository.mail.fl_str_mv bjid@bjid.org.br||lgoldani@ufrgs.br
_version_ 1754209239451041792